Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle
formulation and carboplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as
bevacizumab, can block tumor growth in different ways. Some find tumor cells and help kill
them or carry tumor-killing substances to them. Others interfere with the ability of tumor
cells to grow and spread. Bevacizumab may also stop the growth of breast cancer by blocking
blood flow to the tumor. Giving combination chemotherapy together with bevacizumab before
surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
removed. Giving bevacizumab after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial is studying the side effects and how well giving paclitaxel
albumin-stabilized nanoparticle formulation and carboplatin together with bevacizumab works
in treating women undergoing surgery for stage II or stage III breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Ewa Mrozek Ohio State University Comprehensive Cancer Center